In this phase II study , patients with stage IIIB/IV non-small-cell lung cancer were randomly assigned ( 1:1:1 ) to receive LY293111 ( 200 mg twice daily [ 200 LY293111 ] or 600 mg twice daily [ 600 LY293111 ] ) or placebo for 7 days , followed by concurrent cisplatin ( 75 mg/m2 ; day 1 ) and gemcitabine ( 1250 mg/m2 ; days 1 and 8 ) , every 21 days.The primary endpoint was progression-free survival , ( PFS ) , with 75 % power to detect 33 % improvement compared with placebo ( 5 months ) .